Redmile Group, LLC

Redmile Group, LLC has an estimated net worth of $301 Million. This is based on reported shares across multiple companies, which include ALDER BIOPHARMACEUTICALS INC, XERIS PHARMACEUTICALS INC, RayzeBio, Inc., Allakos Inc., Science 37 Holdings, Inc., PLIANT THERAPEUTICS, INC., Stoke Therapeutics, Inc., Absci Corp, Adagio Therapeutics, Inc., Gritstone Oncology, Inc., Entrada Therapeutics, Inc., Repare Therapeutics Inc., Allovir, Inc., IGM Biosciences, Inc., Verve Therapeutics, Inc., Nurix Therapeutics, Inc., Akero Therapeutics, Inc., Replimune Group, Inc., AMICUS THERAPEUTICS INC, FATE THERAPEUTICS INC, Kymera Therapeutics, Inc., Beam Therapeutics Inc., Augmedix, Inc., Neoleukin Therapeutics, Inc., Syros Pharmaceuticals, Inc., Atreca, Inc., VAPOTHERM INC, Shattuck Labs, Inc., TCR2 THERAPEUTICS INC., HOOKIPA Pharma Inc., Cabaletta Bio, Inc., Annexon, Inc., MedAvail Holdings, Inc., Aprea Therapeutics, Inc., ARRAY BIOPHARMA INC, Zymeworks Inc., ADC Therapeutics SA, and Atara Biotherapeutics, Inc..

2024 was Redmile Group, LLC's most active year for acquiring shares with 52 total transactions. Redmile Group, LLC's most active month to acquire stocks was the month of May. 2024 was Redmile Group, LLC's most active year for disposing of shares, totalling 25 transactions. Redmile Group, LLC's most active month to dispose stocks was the month of September. 2020 saw Redmile Group, LLC paying a total of $190,530,705.65 for 23,089,273 shares, this is the most they've acquired in one year. In 2024 Redmile Group, LLC cashed out on 44,717,293 shares for a total of $86,549,332.31, their largest year based on trade value.